EVOLUS, INC. Operating Cash Flow
EVOLUS, INC. (EOLS) reported Operating Cash Flow of -$13.54 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-05
- EVOLUS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$3.59M.
- EVOLUS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$9.95M.
- EVOLUS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was $12.83M, a 166.78% increase year-over-year.
- EVOLUS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$14.67M.
- EVOLUS, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$42.27M.
- EVOLUS, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$18.00M.
- EVOLUS, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$34.01M.
- EVOLUS, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$84.91M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$3.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$13.54M 10-Q · filed 2026-08-05 | -$712.00K derived: sum of 3 quarters · filed 2026-08-05 | -$15.38M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | -$9.95M 10-Q · filed 2026-05-04 | $2.88M derived: sum of 2 quarters · filed 2026-05-04 | -$11.79M derived: sum of 3 quarters · filed 2026-05-04 | -$36.59M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-12-31 | $12.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$1.84M derived: sum of 2 quarters · filed 2026-03-03 | -$26.63M derived: sum of 3 quarters · filed 2026-08-05 | -$42.27M 10-K · filed 2026-03-03 | |
| 2025-09-30 | -$14.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$39.46M derived: sum of 2 quarters · filed 2026-08-05 | -$55.09M 10-Q · filed 2025-11-05 | -$50.28M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-06-30 | -$24.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$40.42M 10-Q · filed 2026-08-05 | -$35.62M derived: sum of 3 quarters · filed 2026-08-05 | -$41.34M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-03-31 | -$15.63M 10-Q · filed 2026-05-04 | -$10.82M derived: sum of 2 quarters · filed 2026-05-04 | -$16.55M derived: sum of 3 quarters · filed 2026-05-04 | -$23.02M derived: sum of 4 quarters · filed 2026-05-04 | |
| 2024-12-31 | $4.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$914.00K derived: sum of 2 quarters · filed 2026-03-03 | -$7.38M derived: sum of 3 quarters · filed 2026-03-03 | -$18.00M 10-K · filed 2026-03-03 | |
| 2024-09-30 | -$5.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$12.19M derived: sum of 2 quarters · filed 2025-11-05 | -$22.81M 10-Q · filed 2025-11-05 | -$21.99M derived: sum of 4 quarters · filed 2026-03-03 | |
| 2024-06-30 | -$6.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$17.09M 10-Q · filed 2025-08-05 | -$16.27M derived: sum of 3 quarters · filed 2026-03-03 | -$17.20M derived: sum of 4 quarters · filed 2026-03-03 | |
| 2024-03-31 | -$10.62M 10-Q · filed 2025-05-07 | -$9.80M derived: sum of 2 quarters · filed 2026-03-03 | -$10.73M derived: sum of 3 quarters · filed 2026-03-03 | -$24.04M derived: sum of 4 quarters · filed 2026-03-03 | |
| 2023-12-31 | $813.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$111.00K derived: sum of 2 quarters · filed 2026-03-03 | -$13.42M derived: sum of 3 quarters · filed 2026-03-03 | -$34.01M 10-K · filed 2026-03-03 | |
| 2023-09-30 | -$924.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$14.23M derived: sum of 2 quarters · filed 2024-11-06 | -$34.82M 10-Q · filed 2024-11-06 | -$43.59M derived: sum of 4 quarters · filed 2025-03-04 | |
| 2023-06-30 | -$13.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-31 | -$33.90M 10-Q · filed 2024-07-31 | -$42.67M derived: sum of 3 quarters · filed 2025-03-04 | -$59.72M derived: sum of 4 quarters · filed 2025-03-04 | |
| 2023-03-31 | -$20.59M 10-Q · filed 2024-05-07 | -$29.36M derived: sum of 2 quarters · filed 2025-03-04 | -$46.41M derived: sum of 3 quarters · filed 2025-03-04 | -$67.30M derived: sum of 4 quarters · filed 2025-03-04 | |
| 2022-12-31 | -$8.77M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | -$25.82M derived: sum of 2 quarters · filed 2025-03-04 | -$46.71M derived: sum of 3 quarters · filed 2025-03-04 | -$84.91M 10-K · filed 2025-03-04 | |
| 2022-09-30 | -$17.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$37.94M derived: sum of 2 quarters · filed 2023-11-07 | -$76.14M 10-Q · filed 2023-11-07 | -$85.18M derived: sum of 4 quarters · filed 2023-11-07 | |
| 2022-06-30 | -$20.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | -$59.09M 10-Q · filed 2023-08-02 | -$68.13M derived: sum of 3 quarters · filed 2023-08-02 | -$100.26M derived: sum of 4 quarters · filed 2023-08-02 | |
| 2022-03-31 | -$38.20M 10-Q · filed 2023-05-09 | -$47.24M derived: sum of 2 quarters · filed 2023-05-09 | -$79.37M derived: sum of 3 quarters · filed 2023-05-09 | -$63.25M derived: sum of 4 quarters · filed 2023-05-09 | |
| 2021-12-31 | -$9.04M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | -$41.17M derived: sum of 2 quarters · filed 2023-03-08 | -$25.05M derived: sum of 3 quarters · filed 2023-03-08 | -$33.39M 10-K · filed 2023-03-08 | |
| 2021-09-30 | -$32.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$16.01M derived: sum of 2 quarters · filed 2022-11-08 | -$24.34M 10-Q · filed 2022-11-08 | -$26.61M derived: sum of 4 quarters · filed 2022-11-08 | |
| 2021-06-30 | $16.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | $7.78M 10-Q · filed 2022-08-02 | $5.51M derived: sum of 3 quarters · filed 2022-08-02 | -$8.20M derived: sum of 4 quarters · filed 2022-08-02 | |
| 2021-03-31 | -$8.34M 10-Q · filed 2022-05-10 | -$10.60M derived: sum of 2 quarters · filed 2022-05-10 | -$24.31M derived: sum of 3 quarters · filed 2022-05-10 | -$38.26M derived: sum of 4 quarters · filed 2022-05-10 | |
| 2020-12-31 | -$2.27M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | -$15.98M derived: sum of 2 quarters · filed 2022-03-03 | -$29.92M derived: sum of 3 quarters · filed 2022-03-03 | -$57.87M 10-K · filed 2022-03-03 | |
| 2020-09-30 | -$13.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | -$27.66M derived: sum of 2 quarters · filed 2021-11-02 | -$55.60M 10-Q · filed 2021-11-02 | -$71.53M derived: sum of 4 quarters · filed 2021-11-02 | |
| 2020-06-30 | -$13.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | -$41.89M 10-Q · filed 2021-08-04 | -$57.81M derived: sum of 3 quarters · filed 2021-08-04 | -$82.92M derived: sum of 4 quarters · filed 2021-08-04 | |
| 2020-03-31 | -$27.95M 10-Q · filed 2021-05-12 | -$43.87M derived: sum of 2 quarters · filed 2021-05-12 | -$68.97M derived: sum of 3 quarters · filed 2021-05-12 | -$102.13M derived: sum of 4 quarters · filed 2021-05-12 | |
| 2019-12-31 | -$15.92M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | -$41.02M derived: sum of 2 quarters · filed 2021-03-25 | -$74.18M derived: sum of 3 quarters · filed 2021-03-25 | -$93.38M 10-K · filed 2021-03-25 | |
| 2019-09-30 | -$25.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | -$58.26M derived: sum of 2 quarters · filed 2020-10-29 | -$77.46M 10-Q · filed 2020-10-29 | -$89.47M derived: sum of 4 quarters · filed 2020-10-29 | |
| 2019-06-30 | -$33.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | -$52.36M 10-Q · filed 2020-08-10 | -$64.36M derived: sum of 3 quarters · filed 2020-08-10 | -$70.16M derived: sum of 4 quarters · filed 2020-08-10 | |
| 2019-03-31 | -$19.20M 10-Q · filed 2020-05-11 | -$31.21M derived: sum of 2 quarters · filed 2020-05-11 | -$37.00M derived: sum of 3 quarters · filed 2020-05-11 | -$42.67M derived: sum of 4 quarters · filed 2020-05-11 | |
| 2018-12-31 | -$12.01M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | -$17.80M derived: sum of 2 quarters · filed 2020-02-25 | -$23.47M derived: sum of 3 quarters · filed 2020-02-25 | -$25.67M 10-K · filed 2020-02-25 | |
| 2018-09-30 | -$5.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | -$11.46M derived: sum of 2 quarters · filed 2019-11-04 | -$13.66M 10-Q · filed 2019-11-04 | -$14.66M derived: sum of 4 quarters · filed 2019-11-04 | |
| 2018-06-30 | -$5.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-12 | -$7.87M 10-Q · filed 2019-08-12 | -$7.86M 10-Q · filed 2018-08-02 | -$8.87M derived: sum of 3 quarters · filed 2019-08-12 | -$12.29M derived: sum of 4 quarters · filed 2019-08-12 |
| 2018-03-31 | -$2.20M 10-Q · filed 2019-05-01 | -$3.20M derived: sum of 2 quarters · filed 2019-05-01 | -$6.63M derived: sum of 3 quarters · filed 2019-05-01 | -$9.85M derived: sum of 4 quarters · filed 2019-05-01 | |
| 2017-12-31 | -$1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-20 | -$4.43M derived: sum of 2 quarters · filed 2019-03-20 | -$7.64M derived: sum of 3 quarters · filed 2019-03-20 | -$13.22M 10-K · filed 2019-03-20 | |
| 2017-09-30 | -$3.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | -$6.64M derived: sum of 2 quarters · filed 2018-11-05 | -$12.22M 10-Q · filed 2018-11-05 | ||
| 2017-06-30 | -$3.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | -$8.79M 10-Q · filed 2018-08-02 | |||
| 2017-03-31 | -$5.58M 10-Q · filed 2018-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |